Latest Breaking News On - சியாரா ருஸ்ஸோ - Page 3 : comparemela.com

uniQure Inc.: uniQure announces closing of commercialization and license agreement with CSL Behring Upfront payment of $450 million due to uniQure by May 13, 2021 LEXINGTON, Mass. and AMSTERDAM, May 06, 2021N.V., expired on May 5, 2021, and the agreement became fully effective today, May 6, 2021. The agreement was contingent on completion of review under antitrust laws in the United States, Australia, and the United Kingdom. The antitrust review process is now complete in all three countries. As a global leader in hematology and thrombosis, CSL Behring is an ideal commercial partner, and we are excited to embark on our relationship together with a shared goal of delivering this potentially transformative therapy to patients around the world living with hemophilia B, stated Matt Kapusta, chief executive officer of uniQure. This transaction positions etranacogene dezaparvovec to be made available to the largest number of hemophilia B patients as quickly as possible and provides u

United statesUnited kingdomNoord hollandChiara russoMariae cantorMatt kapustaTom maloneQure forward lookingQuarterly reportQure contactsஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்நூற்த் ஹாலண்ட்சியாரா ருஸ்ஸோடோம் மலோந்கர் முன்னோக்கி பார்க்கிறது